Kidney Medicine · Jan 8, 2026

Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials

By Chiang YC, Dai DF, Chiu YW et al.

RATIONALE & OBJECTIVE: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide cardiovascular and renal benefits in individuals with or without type 2 diabetes. This systematic review and meta-analysis investigated the risks of acute kidney injury and other adverse events (AEs) associated with SGLT2is across diverse populations. STUDY DESIGN: Systematic review and meta-analysis of randomized controlled trials (RCTs). SETTING & STUDY POPULATIONS: Thirteen RCTs comprising 84,581 participants were included. The studies encompassed diverse populations, varying in diabetes status, presence of chronic kidney disease, and SGLT2i dosages. SELECTION CRITERIA FOR STUDIES: We included RCTs published through December 31, 2023, that evaluated the safety and efficacy of SGLT2is and reported renal and nonrenal adverse outcomes. DATA EXTRACTION: Two reviewers independently extracted data and resolved discrepancies by consensus, focusing on renal and nonrenal AEs and subgroup analyses. ANALYTICAL APPROACH: Random-effects meta-analysis was performed to estimate pooled relative risks or odds ratios with 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic. RESULTS: SGLT2is were associated with a 20% reduction in the risk of acute kidney injury (relative risk, 0.80; 95% CI, 0.74-0.87), with low between-study heterogeneity, supporting a consistent renoprotective effect. Among patients with chronic kidney disease, the risk of renal composite outcomes was also significantly reduced (odds ratio, 0.70; 95% CI, 0.62-0.79). However, treatment was associated with increased risks of genital infections (P < 0.001), urinary tract infections (P = 0.03), diabetic ketoacidosis (P < 0.001), and hypovolemia (P = 0.008). No significant differences were observed for hypoglycemia (P = 0.08) or lower limb amputation (P = 0.07). LIMITATIONS: Variability in study design, definitions of AEs, and patient baseline characteristics may influence the findings. CONCLUSIONS: SGLT2is conferred substantial renoprotective benefits but increases the risk of certain nonrenal AEs. Tailored treatment and close monitoring are crucial to ensure safety and efficacy, especially in high-risk patients.

doi.org/10.1016/j.xkme.2026.101248Open accessPubMed 41767694Interventions

AgingResearch.News